



Disclosure of total number of voting rights and number of shares in the capital at March 31, 2010

Paris, April 9, 2010 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
March 31, 2010	12, 898,334	Theoretical number of voting rights: 12, 898,334 (including treasury shares) Number of real voting rights: 12, 860,399 (without treasury shares)

About BioAlliance Pharma

BioAlliance Pharma SA is a company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues.

BioAlliance Pharma SA

Dominique Costantini, President and CEO
 Tel.: +33 1 45 58 76 01
 dominique.costantini@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
 Tel.: +33 6 64 18 99 59
 caroline@alizerp.com

Nicolas Fellmann, CFO
 Tel.: +33 1 45 58 71 00
 nicolas.fellmann@bioalliancepharma.com